5.63
1.74 (44.73%)
| Previous Close | 3.89 |
| Open | 5.07 |
| Volume | 33,040,226 |
| Avg. Volume (3M) | 1,268,754 |
| Market Cap | 714,515,392 |
| Price / Sales | 1.27 |
| Price / Book | 2.30 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -3.46% |
| Operating Margin (TTM) | -23.28% |
| Diluted EPS (TTM) | -0.160 |
| Quarterly Revenue Growth (YOY) | -21.20% |
| Quarterly Earnings Growth (YOY) | 289.40% |
| Total Debt/Equity (MRQ) | 11.58% |
| Current Ratio (MRQ) | 4.12 |
| Operating Cash Flow (TTM) | 4.43 M |
| Levered Free Cash Flow (TTM) | -4.36 M |
| Return on Assets (TTM) | 0.70% |
| Return on Equity (TTM) | -4.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Organogenesis Holdings Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 46.49% |
| % Held by Institutions | 54.09% |
| 52 Weeks Range | ||
| Median | 7.00 (24.33%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 26 Sep 2025 | 7.00 (24.33%) | Buy | 4.10 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2025 | Announcement | Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance |
| 03 Nov 2025 | Announcement | Organogenesis Applauds CMS’s Significant Step In Payment Reform |
| 31 Oct 2025 | Announcement | Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 01 Oct 2025 | Announcement | Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 |
| 25 Sep 2025 | Announcement | Organogenesis Provides Update on Second Phase 3 ReNu® Study |
| 27 Aug 2025 | Announcement | Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |